Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Lisa D. Cleary"'
Autor:
Lakshmi Srinivasan, Yvonne Ware, Kelledy Manson, Asaf Poran, Benjamin Trapp, Joel Greshock, Mark M. Awad, Dominik Barthelme, Dewi Harjanto, Victoria Kohler, Ying S. Ting, Richard B. Gaynor, Yuting Huang, Matthew D. Hellmann, Samantha J. Turnbull, Siwen Hu-Lieskovan, Ed Fritsch, Meghan E. Bushway, Jessica J. Lin, Lisa D. Cleary, Bartosz Chmielowski, Zhengping Huang, Michael S. Rooney, Terence W. Friedlander, Rana H. Besada, Patrick A. Ott, Zakaria S. Khondker, Mark DeMario, Kristen N. Balogh, Aung Naing, Melissa A. Moles, Riley R. Curran, Kim Margolin, Nina Bhardwaj, Tracey E. Sciuto, Jesse Z. Dong, Ramaswamy Govindan, Julian Scherer, Amy Wanamaker
Publikováno v:
Cell. 183(2)
Summary Neoantigens arise from mutations in cancer cells and are important targets of T cell-mediated anti-tumor immunity. Here, we report the first open-label, phase Ib clinical trial of a personalized neoantigen-based vaccine, NEO-PV-01, in combina
Autor:
Gerald Steven Falchook, Erika Manyak, Kristen McEachern, Viviana Bozon, Sudha Parasuraman, Kristy Kuplast-Barr, Luke Utley, Lisa D. Cleary, Timothy A. Yap, Melissa Lynne Johnson, Manish R. Patel
Publikováno v:
Journal of Clinical Oncology. 39:3000-3000
3000 Background: Targeting cytosolic nucleic acid sensing pathways and the Type I interferon (IFN) response is an emerging therapeutic strategy in oncology. PARP7 is a member of the monoPARP class of enzymes and a newly identified negative regulator
Autor:
Meghan E. Bushway, Ying Sonia Ting, Rana H. Besada, Tracey E. Sciuto, Jasmina Prabhakara, Julian Scherer, Kristen N. Balogh, April Lamb, Jennifer A. Kaplan, Lisa D. Cleary, Melissa A. Moles, Sarah E. Church, Yuqi Ren, Xing Ren, Richard B. Gaynor, Matthew J. Goldstein, Les H. Brail, Joel Greshock, Lakshmi Srinivasan
Publikováno v:
Cancer Research. 79:5006-5006
Background: Neoantigens arise from DNA mutations in cancer cells and are important targets for T cell mediated anti-tumor immunity. NEO-PV-01 is a personal neoantigen vaccine of up to 20 peptides designed based on a patient’s neoantigen and HLA pro
Autor:
Riley R. Curran, Matthew J. Goldstein, Meghan E. Bushway, Kristen N. Balogh, Dewi Harjanto, April Lamb, Rana H. Besada, Tracey E. Sciuto, Joel Greshock, Samantha J. Gates, Yvonne Ware, Lisa D. Cleary, Siwen Hu-Lieskovan, Richard B. Gaynor, Michael S. Rooney, Julian Scherer, Lakshmi Srinivasan, Victoria R. Kohler, Aung Naing, Ying S. Ting, Yuting Huang, Melissa A. Moles, Zhengping Huang, Les H. Brail, Patrick A. Ott
Publikováno v:
Cancer Research. 79:942-942
Background: Neoantigens arise from DNA mutations in cancer cells and are important targets for T cell mediated anti-tumor immunity. NEO-PV-01 is a personal neoantigen vaccine of up to 20 peptides designed based on a patient’s neoantigen and HLA pro
Autor:
April Lamb, Julian Scherer, Victoria Kohler, Melissa A. Moles, Dominik Barthelme, Richard B. Gaynor, Lisa D. Cleary, Lakshmi Srinivasan, Riley R. Curran, Joel Greshock, Matthew J. Goldstein, Jose G. Martinez, Meghan E. Bushway, Samantha J. Gates, Jesse Z. Dong, Aung Naing, Patrick A. Ott
Publikováno v:
Cancer Research. 78:LB-147
Background: Neoantigens arise from DNA mutations and are critical targets that are presented on the surface of cancer cells for tumor-specific T cell responses. Vaccines targeting neoantigens have the potential to induce de novo and amplify pre-exist
Autor:
David R. Spigel, Ramaswamy Govindan, Richard B. Gaynor, Lisa D. Cleary, Matthew J. Goldstein, Melissa A. Moles, Mark M. Awad
Publikováno v:
Journal of Clinical Oncology. 36:TPS3134-TPS3134
TPS3134Background: Cancer cells contain unique DNA mutations that result in altered amino acid sequences known as neoantigens. Evidence supports a central role for neoantigens as targets for tumor-directed immune responses. Tumor mutational burden as